Avid Bioservices, Inc.
CDMONASDAQHealthcare
$12.49
+$0.00(+0.00%)
Market Cap$798901617
P/E Ratio—
52W High$12.51
52W Low$5.9
Avid Bioservices, Inc. (CDMO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
CDMO · earnings · updated Jun 9, 2026
Latest Earnings
Q4 FY2024Report Date: Dec 10, 2024EPS Actual
-$0.27
Est. -$0.12 · -125.0%
Revenue
$0.03B
Est. $0.03B · -0.9%
Fiscal Period
Q4 FY2024
FY ends December
Report Date
Dec 10, 2024
After Market Close
▼ Miss EPS
CDMO reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$3.83
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$3.83
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Dec 10, 2024 | -$0.12 | -$0.27 | -125.0% | $0.03B | $0.03B | -0.9% |
| ▼ Q3 FY2024 | Sep 9, 2024 | -$0.04 | -$0.09 | -125.0% | $0.04B | $0.04B | -1.4% |
| ▼ Q3 FY2024 | Jul 2, 2024 | -$0.04 | -$1.94 | -5073.3% | $0.04B | $0.04B | +2.0% |
| ▼ Q2 FY2024 | Apr 24, 2024 | -$0.05 | -$0.08 | -71.4% | $0.03B | $0.04B | -19.6% |
| ▼ Q1 FY2024 | Mar 25, 2024 | -$0.05 | -$0.09 | -80.0% | $0.03B | $0.03B | +1.1% |
| ▼ Q4 FY2023 | Dec 7, 2023 | -$0.06 | -$0.15 | -150.0% | $0.03B | $0.03B | -15.3% |
| ▼ Q3 FY2023 | Sep 7, 2023 | -$0.03 | -$0.03 | -9.1% | $0.04B | $0.04B | +4.5% |
| ▲ Q2 FY2023 | Jun 21, 2023 | -$0.02 | $0.05 | +350.0% | $0.04B | $0.04B | +2.3% |
Q4 FY2024
Dec 10, 2024Miss
EPS Actual
-$0.27
EPS Est.
-$0.12
EPS Surpr.
-125.0%
Revenue
$0.03B
Q3 FY2024
Sep 9, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.04
EPS Surpr.
-125.0%
Revenue
$0.04B
Q3 FY2024
Jul 2, 2024Miss
EPS Actual
-$1.94
EPS Est.
-$0.04
EPS Surpr.
-5073.3%
Revenue
$0.04B
Q2 FY2024
Apr 24, 2024Miss
EPS Actual
-$0.08
EPS Est.
-$0.05
EPS Surpr.
-71.4%
Revenue
$0.03B
Q1 FY2024
Mar 25, 2024Miss
EPS Actual
-$0.09
EPS Est.
-$0.05
EPS Surpr.
-80.0%
Revenue
$0.03B
Q4 FY2023
Dec 7, 2023Miss
EPS Actual
-$0.15
EPS Est.
-$0.06
EPS Surpr.
-150.0%
Revenue
$0.03B
Q3 FY2023
Sep 7, 2023Miss
EPS Actual
-$0.03
EPS Est.
-$0.03
EPS Surpr.
-9.1%
Revenue
$0.04B
Q2 FY2023
Jun 21, 2023Beat
EPS Actual
$0.05
EPS Est.
-$0.02
EPS Surpr.
+350.0%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.09 | $0.09 | $0.09 | 1 |
| Q1 FY2027 | $0.03 | $0.03 | $0.03 | 1 |
| Q4 FY2026 | $-0.02 | $-0.02 | $-0.02 | 1 |
| Q3 FY2026 | $0.03 | $0.03 | $0.03 | 1 |
| Q2 FY2026 | $0.02 | $0.02 | $0.02 | 1 |
| Q1 FY2026 | $-0.03 | $-0.03 | $-0.03 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q2 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q1 FY2027 | $0.1B | $0.1B | $0.1B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.1B | $0.1B | $0.1B | 1 |
| Q2 FY2026 | $0.1B | $0.1B | $0.1B | 2 |
| Q1 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q4 FY2024 | Dec 10, 2024 | -125.0% | $12.27 | $12.31 | +0.33% |
| ▼ Q3 FY2024 | Sep 9, 2024 | -125.0% | $8.83 | $8.95 | +1.36% |
| ▼ Q3 FY2024 | Jul 2, 2024 | -5073.3% | $7.12 | $6.70 | -5.90% |
| ▼ Q2 FY2024 | Apr 24, 2024 | -71.4% | $6.68 | $6.83 | +2.25% |
| ▼ Q1 FY2024 | Mar 25, 2024 | -80.0% | $6.73 | $6.83 | +1.49% |
| ▼ Q4 FY2023 | Dec 7, 2023 | -150.0% | $5.20 | $5.29 | +1.73% |
| ▼ Q3 FY2023 | Sep 7, 2023 | -9.1% | $12.20 | $11.62 | -4.75% |
| ▲ Q2 FY2023 | Jun 21, 2023 | +350.0% | $16.03 | $15.57 | -2.87% |
Q4 FY2024+0.33%
Report Date
Dec 10, 2024
EPS Beat/Miss
-125.0%
Price Before
$12.27
Price After
$12.31
Q3 FY2024+1.36%
Report Date
Sep 9, 2024
EPS Beat/Miss
-125.0%
Price Before
$8.83
Price After
$8.95
Q3 FY2024-5.90%
Report Date
Jul 2, 2024
EPS Beat/Miss
-5073.3%
Price Before
$7.12
Price After
$6.70
Q2 FY2024+2.25%
Report Date
Apr 24, 2024
EPS Beat/Miss
-71.4%
Price Before
$6.68
Price After
$6.83
Q1 FY2024+1.49%
Report Date
Mar 25, 2024
EPS Beat/Miss
-80.0%
Price Before
$6.73
Price After
$6.83
Q4 FY2023+1.73%
Report Date
Dec 7, 2023
EPS Beat/Miss
-150.0%
Price Before
$5.20
Price After
$5.29
Q3 FY2023-4.75%
Report Date
Sep 7, 2023
EPS Beat/Miss
-9.1%
Price Before
$12.20
Price After
$11.62
Q2 FY2023-2.87%
Report Date
Jun 21, 2023
EPS Beat/Miss
+350.0%
Price Before
$16.03
Price After
$15.57
Avg Beat Reaction-2.87%
Avg Miss Reaction-0.50%
Beat Rate1 / 8 quarters
Largest Move-5.90% (Q3 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: CDMO ends December
Avid Bioservices, Inc. (CDMO) most recently reported earnings on December 10, 2024 for Q4 FY2024, posting EPS of $-0.27 — missing the analyst consensus of $-0.12 by -125.0%. The next CDMO earnings date is expected around September 1, 2026.
Each quarter, investors track CDMO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. CDMO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
CDMO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
CDMO earnings · 5 questionsAvid Bioservices, Inc.'s next earnings report is expected around September 1, 2026. CDMO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; CDMO historically reports after market close (AMC).
CDMO earnings datewhen is CDMO earningsCDMO next earnings datewhen does CDMO report earningsCDMO earnings calendar
▸ Source: FMP · Avid Bioservices, Inc. SEC filings · US GAAP · Avid Bioservices, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026